Argenx
ARGX
#402
Rank
NZ$106.41 B
Marketcap
NZ$1,692
Share price
-1.73%
Change (1 day)
3.40%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2026 (TTM): NZ$39.15

According to Argenx 's latest financial reports the company's current EPS (TTM) is NZ$40.87. In 2025 the company made an earnings per share (EPS) of NZ$38.53 an increase over its 2024 EPS that were of NZ$25.45.

EPS history for Argenx from 2011 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$39.151.61%
2025NZ$38.5351.44%
2024NZ$25.45-369.77%
2023NZ-$9.43-60.46%
2022NZ-$23.8663.33%
2021NZ-$14.61-40.37%
2020NZ-$24.50183.47%
2019NZ-$8.64123.09%
2018NZ-$3.8754.93%
2017NZ-$2.5014.07%
2016NZ-$2.1913.05%
2015NZ-$1.94-36.34%
2014NZ-$3.05209.04%
2013NZ-$0.99-33.99%
2012NZ-$1.49185.59%
2011NZ-$0.52